Search

Virtual TRACTS Moves the ten hour testing day at the VA Hospital into three online sessions from the comfort of your home. One, you will meet with a research assistant and complete a series of questionnaires to provide our psychologists with important background information about your military...

Dear Fellow Postdocs: Join us with BPDA & HMPDA to hear from three PhDs who transitioned from bench work to Environmental Health & Safety, supporting the essential needs of life science labs in Boston. When: Dec 13th, 2022, 12-1 pm, Tuesday Where : 240 Longwood Ave, Boston, MA 02115, HMS Cannon Room...

We recently identified GDF15 as a hormone released in response to hypoglycemia, which may contribute to symptoms experienced during hypoglycemia. This paper was published in Cell Reports Medicine in March 2026 (Pubmed, PMID 41806840). Congratulations to first author Rafael Ferraz-Bannitz PhD and the...

Dear Colleagues, In this issue of eye Insights, we take a close look at posterior uveitis. Inside, you’ll find techniques and tips for evaluating and managing patients with this condition. Due to its many etiologies, posterior uveitis can be challenging to treat until the cause of the inflammation...

The most common symptoms of posterior uveitis are blurred vision and floaters, and the most common signs are chorioretinal infiltrates and vitreous cells. Posterior uveitis is diagnosed by slit lamp examination and indirect ophthalmoscopy. Imaging modalities, including fundus autofluorescence...

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...

The effect of sodium oxybate (Xyrem ®) in a patient with laryngeal dystonia and voice tremor before (A) and after (B) drug intake (S imonyan K and Frucht SJ, Tremor Other Hyperkin Dis, 2013 ) Current treatment of laryngeal dystonia (LD) is limited to the temporary management of voice symptoms with...

POSTDOCTORAL FELLOWSHIP IN DECISION MODELING AND CANCER SURVIVORSHIP The Division of General Pediatrics at Boston Children’s Hospital is seeking a highly motivated and capable decision scientist, epidemiologist or outcomes researcher with a strong interest in cancer survivorship. The fellow will...